1\/6
\n\uff11\uff09\tYOGI UMBARAWAN
\nVital role of glucose as biomass synthesis substrate in CD36 deficient heart under pressure oberload.<\/p>\n
\uff12\uff09\tSeki M,Koitabashi N,Furukawa N,Sunaga H,Yokoyama Y,Kurabayashi M.
\nSmad3 Activation in Periostin Expressing Cells Contributes Pathogenesis of PAH<\/p>\n
\uff13\uff09 Iso T,Yogi Umbawaran,Sunaga H,Matsui H,Koitabashi N,Kurabayashi M.
\nSuppression of cardiac catabolism with accumulation of energy substrates during LPS-induced cardiac dysfunction<\/p>\n
Tadashi Nakajima, Yoshiaki Kaneko, Reika Kawabata, Takashi Iizuka, Shuntato Tamura, Yukie Sano, Hiroshi Hasegawa, Tadanobu Irie, Yoshiaki Ohyama,Yoshinao Sugai, Koji Kumagai, Shigeto Naito, Masahiko Nishiyama, Masahiko Kurabayashi.
\nEpinephrine-induced marked QT prolongation in patients with type-3 long QT syndrome.<\/p>\n
\uff11)\t\u5c0f\u677f\u6a4b\u7d00\u901a\u3001\u661f\u91ce\u6b63\u9053\u3001\u4e80\u7530\u9ad8\u5fd7\u3001\u5c71\u53e3\u667a\u7f8e\u3001\u798f\u4e95\u5927\u7950\u3001\u6885\u5c71\u3000\u6566\u3001\u8239\u7530\u7adc\u4e00\u3001\u5ca1\u7530\u5065\u6b21\u3001\u53e4\u5e84\u77e5\u5df1\u3001\u5009\u6797\u6b63\u5f66
\n\u8840\u7ba1\u578b\u30a8\u30fc\u30e9\u30b9\u30fb\u30c0\u30f3\u30ed\u30b9\u75c7\u5019\u7fa4\u5408\u4f75\u598a\u5a20\u306e\uff12\u4f8b<\/p>\n
\uff12)\t\u53cd\u753a\u79c0\u7f8e\u3001\u5c0f\u677f\u6a4b\u7d00\u901a\u3001\u4e2d\u91ce\u8003\u82f1\u3001\u4f50\u91ce\u5e78\u6075\u3001\u539f\u7530\u667a\u6210\u3001\u9577\u5742\u5d07\u53f8\u3001\u6885\u5c71\u3000\u6566\u3001\u4f34\u91ce\u6f64\u4e00\u3001\u9ed2\u6ca2\u5e78\u55e3\u3001\u8239\u7530\u7adc\u4e00\u3001\u7b20\u9593\u3000\u5468\u3001\u9ad8\u9593\u5178\u660e\u3001\u5009\u6797\u6b63\u5f66
\n\u91cd\u75c7\u80ba\u9ad8\u8840\u5727\u75c7\u3092\u4f34\u3046\u5fc3\u623f\u4e2d\u9694\u6b20\u640d\u75c7\u306b\u5bfe\u3057Trear and Repair\u3092\u884c\u3063\u305f\u4e00\u4f8b<\/p>\n
2\/3
\nSato M.
\nAssessment of focal myocardial scar by native T1 value and extra cellular volume in patient with cardiac sarcoidosis:comparison with late gadolinium enhancement cardiac imaging.<\/p>\n
2\/12<\/p>\n
\uff11)\t\u7530\u6751\u5cfb\u592a\u90ce\u3001\u5165\u6c5f\u5fe0\u4fe1\u3001\u98ef\u585a\u8cb4\u58eb\u3001\u7530\u6751\u672a\u592e\u3001\u98ef\u5cf6\u8cb4\u53f2\u3001\u592a\u7530\u660c\u6a39\u3001\u9f4b\u85e4\u7ae0\u5b8f\u3001\u4e2d\u5cf6\u3000\u5fe0\u3001\u5009\u6797\u6b63\u5f66\u3001\u91d1\u53e4\u5584\u660e
\nAttain 4196 LV lead\u306e\u629c\u53bb\u306e\u969b\u306b\u51a0\u9759\u8108\u6d1e\u672c\u5e79\u3067\u30c8\u30e9\u30c3\u30d7\u3055\u308c\u305f\u4e00\u4f8b\uff0e<\/p>\n
\uff12)\t\u98ef\u585a\u8cb4\u58eb\u3001\u5165\u6c5f\u5fe0\u4fe1\u3001\u7530\u6751\u5cfb\u592a\u90ce\u3001\u7530\u6751\u672a\u592e\u3001\u98ef\u5cf6\u8cb4\u53f2\u3001\u592a\u7530\u660c\u6a39\u3001\u9f4b\u85e4\u7ae0\u5b8f\u3001\u4e2d\u5cf6\u3000\u5fe0\u3001\u5009\u6797\u6b63\u5f66\u3001\u91d1\u53e4\u5584\u660e
\n\u4fee\u6b63\u5927\u8840\u7ba1\u8ee2\u4f4d\u75c7\u306b\u5408\u4f75\u3057\u305f\u5fc3\u5ba4\u7d30\u52d5\u306b\u5bfe\u3057\u3001\u690d\u8fbc\u578b\u9664\u7d30\u52d5\u5668\u79fb\u690d\u8853\u3092\u884c\u3044\u3001\u4e2d\u9577\u671f\u306b\u7d4c\u904e\u89b3\u5bdf\u3057\u3048\u305f2\u4f8b\uff0e<\/p>\n
\u4e2d\u91ce\u8003\u82f1\u3001\u8239\u7530\u7adc\u4e00\u3001\u539f\u7530\u667a\u6210\u3001\u9577\u5742\u5d07\u53f8\u3001\u6885\u5c71\u3000\u6566\u3001\u4f50\u85e4\u4e07\u57fa\u4eba\u3001\u7b20\u9593\u3000\u5468\u3001\u9ad8\u9593\u5178\u660e\u3001\u5009\u6797\u6b63\u5f66
\n\u51a0\u52d5\u8108\u8840\u6813\u3068\u8003\u3048\u3089\u308c\u3066\u3044\u305fCalcified nodule\u306e\u4e00\u4f8b<\/p>\n
Kaneko Y,Nakajima T,Nogami A,Inden Y,Asakawa T,Morishima I,Mizukami A,Irie T,Iizuka T,Tamura S,Ota C,Kanzaki Y,Nakagawa K,Suzuki M,Kurabayashi M.
\nAtypical fast-slow atrioventricular nodal reentrant tachycardia utilizing a slow pathway connected to the right atrial free wall along the tricuspid annulus.<\/p>\n
3\/23<\/p>\n
\uff11)\t\u9ad8\u6a4b\u4f38\u5f25\u3001\u7b20\u9593\u3000\u5468\u3001\u4f50\u85e4\u4e07\u57fa\u4eba\u3001\u4e2d\u91ce\u8003\u82f1\u3001\u4f50\u91ce\u5e78\u6075\u3001\u9577\u5742\u5d07\u53f8\u3001\u6885\u5c71\u3000\u6566\u3001\u4f34\u91ce\u6f64\u4e00\u3001\u8239\u7530\u7adc\u4e00\u3001\u9ad8\u9593\u5178\u660e\u3001\u5c0f\u677f\u6a4b\u7d00\u901a\u3001\u5009\u6797\u6b63\u5f66\u3001\u5e83\u4e95\u77e5\u6b73
\nEffects of Nicorandil on Sympathetic Berve Activety and Incidence of Cardiac Death Events in Patients with ST-Segment Elevation Myocardial Infarction.<\/p>\n
\uff12)\t\u7b20\u9593\u3000\u5468\u3001\u4f50\u85e4\u4e07\u57fa\u4eba\u3001\u4e2d\u91ce\u8003\u82f1\u3001\u4f50\u91ce\u5e78\u6075\u3001\u9577\u5742\u5d07\u53f8\u3001\u6885\u5c71\u3000\u6566\u3001\u4f34\u91ce\u6f64\u4e00\u3001\u8239\u7530\u7adc\u4e00\u3001\u9ad8\u9593\u5178\u660e\u3001\u5c0f\u677f\u6a4b\u7d00\u901a\u3001\u5009\u6797\u6b63\u5f66
\nEffects of Adding Eplerenone to Standard Therapy on Sympathetic Nerve Activity and Myocardial Collagen Metabolism in Chronic Heart Failure Patients<\/p>\n
\uff13)\t\u9808\u6c38\u6d69\u7ae0\u3001\u5c0f\u4fdd\u65b9\u3000\u512a\u3001\u6839\u5cb8\u4e00\u660e\u3001\u5c0f\u5ddd\u54f2\u4e5f\u3001\u78ef\u3000\u9054\u4e5f\u3001\u5c0f\u677f\u6a4b\u7d00\u901a\u3001\u5009\u6797\u6b63\u5f66
\nCirclating Ketone Body as a Novel biomarker for Worse Clinical Outcomes in Hemodialysis Patients<\/p>\n
\uff14)\t\u7b20\u9593\u3000\u5468\u3001\u4f50\u85e4\u4e07\u57fa\u4eba\u3001\u4e2d\u91ce\u8003\u82f1\u3001\u4f50\u91ce\u5e78\u6075\u3001\u9577\u5742\u5d07\u53f8\u3001\u6885\u5c71\u3000\u6566\u3001\u4f34\u91ce\u6f64\u4e00\u3001\u8239\u7530\u7adc\u4e00\u3001\u9ad8\u9593\u5178\u660e\u3001\u5c0f\u677f\u6a4b\u7d00\u901a\u3001\u5009\u6797\u6b63\u5f66
\nAdditive Effect of Ezetimibe and Statin on Myocardial Fatty acid Metabolism after Reperfusion Therapy in Patients with ST-Segment-Elvation Myocardial Infarction<\/p>\n
\uff15)\t\u7b20\u9593\u3000\u5468\u3001\u4f50\u85e4\u4e07\u57fa\u4eba\u3001\u4e2d\u91ce\u8003\u82f1\u3001\u4f50\u91ce\u5e78\u6075\u3001\u9577\u5742\u5d07\u53f8\u3001\u6885\u5c71\u3000\u6566\u3001\u4f34\u91ce\u6f64\u4e00\u3001\u8239\u7530\u7adc\u4e00\u3001\u9ad8\u9593\u5178\u660e\u3001\u5c0f\u677f\u6a4b\u7d00\u901a\u3001\u5009\u6797\u6b63\u5f66
\nPrediction of Cardiac Dearth Events by Using the smartMIBG-HF Software in Patients with Mild to Moderate Chronic Heart Failure<\/p>\n
\uff16)\t\u7b20\u9593\u3000\u5468\u3001\u4f50\u85e4\u4e07\u57fa\u4eba\u3001\u4e2d\u91ce\u8003\u82f1\u3001\u4f50\u91ce\u5e78\u6075\u3001\u9577\u5742\u5d07\u53f8\u3001\u6885\u5c71\u3000\u6566\u3001\u4f34\u91ce\u6f64\u4e00\u3001\u8239\u7530\u7adc\u4e00\u3001\u9ad8\u9593\u5178\u660e\u3001\u5c0f\u677f\u6a4b\u7d00\u901a\u3001\u5009\u6797\u6b63\u5f66
\nCombined Assessment of Renal Anemia and Stress Myocardial Perfusion Imaging for Prediction of Adverse Events in Chronic Kidney Disease Patients<\/p>\n
\uff17)\t\u7b20\u9593\u3000\u5468\u3001\u4f50\u85e4\u4e07\u57fa\u4eba\u3001\u4e2d\u91ce\u8003\u82f1\u3001\u4f50\u91ce\u5e78\u6075\u3001\u9577\u5742\u5d07\u53f8\u3001\u6885\u5c71\u3000\u6566\u3001\u4f34\u91ce\u6f64\u4e00\u3001\u8239\u7530\u7adc\u4e00\u3001\u9ad8\u9593\u5178\u660e\u3001\u5c0f\u677f\u6a4b\u7d00\u901a\u3001\u5009\u6797\u6b63\u5f66
\nEffects of Adding Eplerenone to Standard Therapy on Sympathetic Nerve Activity and Myocardial Collagen Metabolism in Chronic Heart Failure Patients<\/p>\n
\uff18)\t\u9577\u5742\u5d07\u53f8\u3001\u6885\u5c71\u3000\u6566\u3001\u4f50\u85e4\u4e07\u57fa\u4eba\u3001\u9ad8\u9593\u5178\u660e\u3001\u7b20\u9593\u3000\u5468\u3001\u5c0f\u677f\u6a4b\u7d00\u901a
\nLong-term Outcome of Drug Coated Ballons in Patients with Stent Edge Restenosis<\/p>\n
\uff19)\tMatsuo Y,Kurabayashi M.
\nFollow-up Complication Considering Post-procedural Medication of the Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation<\/p>\n
\uff11\uff10)\tYogi Umbarawan,Mas Rizky AA Syamsunarno,Koitabashi N,Kurabayashi M,Iso T.
\nGlucose is Preferably Utilized for Biomass Synthesis Rather than ATP Production in Pressure-overloaded CD36 Deficient Heart.<\/p>\n
\uff11\uff11)\tTommy Dharmawan,Nakajima T,Iizuka T,Sasaki T,Tamura S,Irie T,Matsui H,Imai M,Niwamae N,Tange S,Kaneko Y,Kurabayashi M.
\nDivergent Molecular Mechanisms of Cardiac Sodium Cannelopathies Exhibiting Brugada Syndrome with Multiple Electrophysiological Phenotypes.<\/p>\n
\uff11\uff12)\tKaneko Y,Nakajima T,Nogami A,Inden Y,Morishima I,Mizukami A,Irie T,Iizuka T,Tamura S,Ota C,Kanzaki Y,Nakagawa K,Suzuki M,Kurabayashi M.
\nAtypical Atrioventricular Nodal Reentrant Tachycardia Utilizing a Slow Pathway Connected to the Right Atrial Free Wall along the Tricuspid Annulus.<\/p>\n
\uff11\uff13)\tTamura S,Kaneko Y,Nakajima T,Irie T,Iizuka T,Kurabayashi M.
\nIs an \u201cOFF and On\u201dSwitch-like Interaction between Typical and Superior Slow Pathways Present?<\/p>\n
\uff11\uff14)\tIso T,Suman Shrestha,Sunaga H,Yogi Umbarawan,Kurabayashi M.
\nKidney is an Essential Organ for Clearance of Circulating FABP4<\/p>\n
\uff11\uff15)\tKaneko Y,Nakajima T,Irie T,Iizuka T,Tamura S,Ohyama T,Nakamura T,Kurabayashi M.
\nDiscrimination of Atypical Atrioventricular Nodal Reentrant Tachycardia from Atrial Tachycardia by Applying V-A-A-V Response Immediately after Ventricular Induction\/Entrainment<\/p>\n
\uff11\uff16)\tIizuka T,Kaneko Y,Nakajima T,Irie T,Tamura S,Kurabayashi M.
\nManifestation of J Wave Induced by Intracoronary Injection of Acetylcholine in Patients with Brugada Syndrome and Early Repolarization Syndrome.<\/p>\n
\uff11\uff17)\tYogi Unbarawan,Mas Rizky AA Syamsunarno,Koitabashi N,Kurabayashi M,Iso T.
\nRobust Activation of Malate-aspartate Shuttle Coupled with Accelerated Glycolysis is Nearly Suppressed by Lipopolysaccharide-induced Cardiac Dysfunction in FABP4\/5 Knockout Mice.<\/p>\n
\uff11\uff18)\tFurukawa N,Koitabashi N,Matsui H,Yokoyama T,Kurabayashi M.
\nSacubitril\/Valsartan(LCA696) Attenuates Passive Myocardial Stiffness in Diabetic Mice Heart
\n3\/24<\/p>\n
\uff11\uff19)\t\u9ad8\u6a4b\u4f38\u5f25\u3001\u7b20\u9593\u3000\u5468\u3001\u4f50\u85e4\u4e07\u57fa\u4eba\u3001\u4e2d\u91ce\u8003\u82f1\u3001\u4f50\u91ce\u5e78\u6075\u3001\u9577\u5742\u5d07\u53f8\u3001\u6885\u5c71\u3000\u6566\u3001\u4f34\u91ce\u6f64\u4e00\u3001\u8239\u7530\u7adc\u4e00\u3001\u9ad8\u9593\u5178\u660e\u3001\u5c0f\u677f\u6a4b\u7d00\u901a\u3001\u5009\u6797\u6b63\u5f66\u3001\u5e83\u4e95\u77e5\u6b73
\nPrediction Formula by Using the smartMIBG-HF Software is Useful for Predicting Sudden Cardiac Death Events in Chronic Heart Failure Patients<\/p>\n
\uff12\uff10)\t\u4e2d\u5cf6\u3000\u5fe0\u3001\u91d1\u53e4\u5584\u660e\u3001\u9ed2\u6ca2\u5e78\u55e3\u3001\u7530\u6751\u5cfb\u592a\u90ce\u3001\u98ef\u585a\u8cb4\u58eb\u3001Tommy Dharmawan\u3001\u5165\u6c5f\u5fe0\u4fe1\u3001\u5009\u6797\u6b63\u5f66
\nHypertraveculation at Left Ventricular Apex is Highly Prevalent and may be Associated with Life-Threatening Ventricular Arrhythmias in Brugada Syndrome<\/p>\n
\uff12\uff11)\tMatsuo Y,Kurabayashi M.
\nCharacteristic Background of Procedure Complication in Left Atrial Appendage Closure<\/p>\n
\uff12\uff12)\tIso T,Haruyama H,Sunaga H,Yogi Umbarawan,Matsui H,Yokoyama T,Kurabayashi M
\nFABP4 and -5 Play a Crucial Role in Exercise Endurance during Prolonged Fasting in Mice<\/p>\n
\uff12\uff13)\tGoto K,Takama N,Kurabayashi M
\nAdaptive-servo Ventilation Therapy is Effective for Elderly Patients with Heart Failure with Ejection Fraction in Real World Data Study.<\/p>\n
\uff12\uff14)\tNakano T,Takama N,Hasegawa H,Kurabayashi M.
\nReassessment after Six Months of Treatment with Adaptive Servo-ventilation can Predict Future Fatal Cardiovascular Events in Patients with HFrEF<\/p>\n
\uff12\uff15)\tToyama T,Kasama S,Nakahara T,Sano H,Sato M,Yamagishi T,Ueda T,SasakiT,Kurabayashi M.
\nWhat are the Most-Important Valures to Predict Major Adverse Cardiovascular,Cerebrovascular,Renal-Events in Patients with Chronic-Kidney-Disease Inculuding Hemodialysis for 2-Yearts?<\/p>\n
\uff12\uff16)\tMatsuo Y,Kumakura H,Kanai H,Iwasaki T,Ichikawa S,Kurabayashi M.
\nPrevalence and Risk Factors for Cerebral Infarction and Carotid Artery Stenosis in Patients with Peripheral Artery Disease<\/p>\n
\uff12\uff17)\t\u9f4b\u85e4\u548c\u7a42\u3001\u6817\u539f \u6df3\u3001\u5bae\u77f3\u88d5\u4ecb\u3001\u7c21\u3000\u4f2f\u61b2\u3001\u6cb3\u53e3\u3000\u5ec9\u3001\u661f\u5d0e\u3000\u6d0b\u3001\u5927\u5cf6\u3000\u8302
\n3mm\u30b9\u30e9\u30a4\u30b9\u77f3\u7070\u5316\u30b9\u30b3\u30a2\uff10\u306e\u60a3\u8005\u306b\u304a\u3044\u30661mm\u30b9\u30e9\u30a4\u30b9\u306b\u3088\u308a\u751f\u77f3\u7070\u5316\u3092\u540c\u5b9a\u3059\u308b\u3000\u610f\u7fa9\u3068\u30d7\u30e9\u30fc\u30af\u306e\u5b58\u5728\u304a\u3088\u3073\u5fc3\u5916\u819c\u8102\u80aa\u3068\u306e\u95a2\u9023\u6027\u306b\u3064\u3044\u3066<\/p>\n
\uff12\uff18)\t\u6b66\u3000\u5bdb\u3001\u5185\u85e4\u6ecb\u4eba\u3001\u4e2d\u6751\u7d18\u898f\u3001\u4e95\u4e0a\u6e80\u7a42\u3001\u65b0\u5cf6\u3000\u6842\u3001\u5143\u7530\u535a\u4e4b\u3001\u5927\u585a\u4f73\u6e80\u3001\u4f50\u3005\u6728\u5065\u4eba\u3001\u5357\u3000\u5065\u592a\u90ce\u3001\u83c5\u4e95\u7fa9\u5c1a\u3001\u718a\u8c37\u6d69\u53f8\u3001\u5927\u5cf6\u3000\u8302
\nUtility of High-Resolution Electro Anatomical Mapping System for Catheter Ablation for Complex Atrial Tachycardia<\/p>\n
\uff12\uff19)\t\u9759\u3000\u6bc5\u4eba\u3001\u5ddd\u4e0a\u3000\u4eae\u3001\u9ad8\u6a4b\u4f38\u5f25\u3001\u5c0f\u6797\u7d18\u751f\u3001\u6751\u7530\u667a\u884c\u3001\u5c0f\u6797\u6d0b\u660e\u3001\u592a\u7530\u660c\u6a39\u3001\u798f\u7530\u5ef6\u662d\u3001\u5e83\u4e95\u77e5\u6b73
\nDiagnostic Ablility of Fusion Image of Non-contrast Coronary Artery MRA and Myocardial Perfusion Imaging SPECT
\n3\/25<\/p>\n
\uff13\uff10)\t\u6238\u7530\u548c\u8fb0\u3001\u7b20\u9593\u3000\u5468\u3001\u4f50\u85e4\u4e07\u57fa\u4eba\u3001\u4e2d\u91ce\u8003\u82f1\u3001\u4f50\u91ce\u5e78\u6075\u3001\u9577\u5742\u5d07\u53f8\u3001\u6885\u5c71\u3000\u6566\u3001\u4f34\u91ce\u6f64\u4e00\u3001\u8239\u7530\u7adc\u4e00\u3001\u9ad8\u9593\u5178\u660e\u3001\u5c0f\u677f\u6a4b\u7d00\u901a\u3001\u5009\u6797\u6b63\u5f66
\nEffects of Selective Aldosterone Blocker Eplerenone on Sympathetic Nerve Activity and Left Ventricular Remodeling in Patients with Chronic Heart Failure<\/p>\n
\uff13\uff11)\t\u6751\u7530\u3000\u8aa0\u3001\u5b89\u9054\u3000\u4ec1\u3001\u4e2d\u51fa\u6cf0\u8f14\u3001\u5927\u5cf6\u3000\u8302\u3001\u5009\u6797\u6b63\u5f66
\nDiabetic Vascular Injury is Consisted of Several Dysglycemic Mechanisms<\/p>\n
\uff13\uff12)\t\u77f3\u6a4b\u6d0b\u5e73\u3001\u7b20\u9593\u3000\u5468\u3001\u4f50\u85e4\u4e07\u57fa\u4eba\u3001\u4e2d\u91ce\u8003\u82f1\u3001\u4f50\u91ce\u5e78\u6075\u3001\u9577\u5742\u5d07\u53f8\u3001\u6885\u5c71\u3000\u6566\u3001\u4f34\u91ce\u6f64\u4e00\u3001\u8239\u7530\u7adc\u4e00\u3001\u9ad8\u9593\u5178\u660e\u3001\u5c0f\u677f\u6a4b\u7d00\u901a\u3001\u5009\u6797\u6b63\u5f66
\nEffects of Selective Aldosterone Blocker Eplerenone on Sympathetic Nerve Activity and Left Ventricular Remodeling in Patients with Acute Myocardial Infarction<\/p>\n
\uff13\uff13)\t\u718a\u5009\u4e45\u592b\u3001\u91d1\u4e95\u5b8f\u7fa9\u3001\u677e\u5c3e\u5f25\u679d\u3001\u5ca9\u5d0e\u4fca\u5f25\u3001\u5e02\u5ddd\u79c0\u4e00\u3001\u5009\u6797\u6b63\u5f66
\n20-year Survival and Fate of the Leg in de Novo Intermittent Claudication<\/p>\n
\uff13\uff14)\tMatsui H,Sunaga H,Iso T,Yokoyama T,Kurabayashi M.
\nInhibition of Fatty Acid Synthase Suppresses Vascular Smooth Muscle Cell Proliferation and Neointimal Formation:Potential Therapeutic Target in Atehrosclerosis<\/p>\n
\uff13\uff15)\tKoitabashi N,Sunaga H,Matsui H,Iso T,Kurabayashi M
\nIdentificaion and Molecular Mechanisms of Fibroblast Growth Factor 21 as a Novel Biomarker for Metabolic Stress in Acute Myocardial Infarction<\/p>\n
\uff13\uff16)\tSorimachi H,Negishi K,Kurosawa K,Yoshida K,Obokata M,Kurabayashi M.
\nSex Difference in Left Ventricular Afterload and Diastolic Function but not with Systolic Function in Patients with Presserved Ejection Fraction<\/p>\n
\uff13\uff17)\tSunaga H,Matsui H,Iso T,Koitabashi N,Shimano H,Yokoyama T,Kurabayashi M.
\nElovl6-driven Fatty Acid Metabolism Regulates Hypertrophic Response in the Heart Subjected to Pressure Overload in Mice<\/p>\n
\uff13\uff18)\tOhyama Y,Imai K,Ichikawa K,Sumiyoshi H,Kurabayashi M.
\nWaist to Height Ratio for Predicting Incident Hypertension in the Japanese General Population<\/p>\n
\uff13\uff19)\tNakajima T,Kaneko Y,Sakai T,Tamura S,Iizuka T,Irie T,Tommy Dharmawan,Imai M,Niwamae N,Tange S,Kurabayashi M.
\nDiverse Precipitating Factors in Secondary Long QT Syndrome.<\/p>\n
\uff14\uff10)\tOhyama Y,Koitabashi N,Nakamura T,Sumita Y,Nakai M,Nakamura F,Nishimura K,Miyamoto Y,Kurabayashi M.
\nEffect of Inferior Vena Cava Filter on Recurrent Venous Thromboembolism in the Japanese Popuration.<\/p>\n
\uff14\uff11)\tAihara K,KanoH,Yajima J,Oikawa Y,Matsuno S,Arita T,Yagi N,Semba H,Suzuki S,Otsuka T,Kato Y,Uejima T,Sasaki K,Matsuhama M,Kunihara T,Yamashita T
\nManagement Strategy and Prognosis of Patients with Positive Treadmill Exercise Testing<\/p>\n
\uff14\uff12)\tAihara K,Kano H,Yajima J,Oikawa Y,Matsuno S,Arita T,Yagi N,Semba H,Suzuki S,Otsuka T,Kato Y,Uejima T,Sasaki K,Matsuhama M,Kunihara T,Yamashita T
\nPrognosis and Prognostic Factor of Patients with False-Positive Treadmill Exercise Testing<\/p>\n
\uff14\uff13)\t\u732a\u718a\u6b63\u7f8e\u3001\u81fc\u7530\u3000\u6ecb\u3001\u751f\u9808\u7fa9\u4e45\u3001\u798f\u53f8\u5149\u6210\u3001\u5c71\u4e0b\u904a\u5e73\u3001\u4e0b\u7530\u7d75\u91cc\u82b1\u3001\u6852\u539f\u62d3\u54c9\u3001\u4e2d\u91ce\u6674\u6075\u3001\u8a2d\u697d\u9054\u5247\u3001\u5b89\u9054\u3000\u4ec1\u3001\u5927\u5cf6\u3000\u8302
\n\u5165\u9662\u9ad8\u9f62\u5fc3\u4e0d\u5168\u60a3\u8005\u306b\u304a\u3051\u308b\u65e9\u671f\u30ec\u30b8\u30b9\u30bf\u30f3\u30b9\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306e\u5b89\u5168\u6027\u3068\u8eab\u4f53\u6a5f\u80fd\u3078\u306e\u5f71\u97ff\u306b\u3064\u3044\u3066<\/p>\n
\uff14\uff14)\t\u4e2d\u6751\u7d18\u898f\u3001\u5185\u85e4\u6ecb\u4eba\u3001\u4f50\u3005\u6728\u5065\u4eba\u3001\u6b66\u3000\u5bdb\u3001\u5927\u585a\u4f73\u6e80\u3001\u5143\u7530\u535a\u4e4b\u3001\u4e95\u4e0a\u6e80\u7a42\u3001\u65b0\u5cf6\u3000\u6842\u3001\u5357\u3000\u5065\u592a\u90ce\u3001\u83c5\u4e95\u7fa9\u5c1a\u3001\u5c71\u4e0b\u82f1\u6cbb\u3001\u718a\u8c37\u6d69\u53f8\u3001\u5927\u5cf6\u3000\u8302
\nUninterrupted versus Interrupted Periprocedural Direct Oral Anticoagulants for AF Ablation:A Prospective Pandomized Study on Post-ablation Thrombolic and Hemorrhagic Events<\/p>\n
\uff14\uff15)\t\u6b66\u3000\u5bdb\u3001\u5185\u85e4\u6ecb\u4eba\u3001\u4e2d\u6751\u7d18\u898f\u3001\u4e95\u4e0a\u6e80\u7a42\u3001\u65b0\u5cf6\u3000\u6842\u3001\u5143\u7530\u535a\u4e4b\u3001\u5927\u585a\u4f73\u6e80\u3001\u4f50\u3005\u6728\u5065\u4eba\u3001\u83c5\u4e95\u7fa9\u5c1a\u3001\u718a\u8c37\u6d69\u53f8\u3001\u5927\u5cf6\u3000\u8302
\nCatheter Ablation of Atrial Fibrillation Improved Cystatin C Based eGFR and Alubuminuriain Patients with Atrial Fibrillation<\/p>\n
\uff14\uff16)\t\u718a\u8c37\u6d69\u53f8\u3001\u5357\u3000\u5065\u592a\u90ce\u3001\u83c5\u4e95\u7fa9\u5c1a\u3001\u5143\u7530\u535a\u4e4b\u3001\u6b66\u3000\u5bdb\u3001\u4e2d\u6751\u7d18\u898f\u3001\u5185\u85e4\u6ecb\u4eba\u3001\u5927\u5cf6\u3000\u8302
\nPredictors of Endothelial Dysfunction in the Patients with Atrial Fibrillation<\/p>\n
\uff14\uff17)\t\u6b66\u3000\u5bdb\u3001\u5185\u85e4\u6ecb\u4eba\u3001\u4e2d\u6751\u7d18\u898f\u3001\u4e95\u4e0a\u6e80\u7a42\u3001\u65b0\u5cf6\u3000\u6842\u3001\u5143\u7530\u535a\u4e4b\u3001\u5927\u585a\u4f73\u6e80\u3001\u4f50\u3005\u6728\u5065\u4eba\u3001\u5357\u3000\u5065\u592a\u90ce\u3001\u83c5\u4e95\u7fa9\u5c1a\u3001\u718a\u8c37\u6d69\u53f8\u3001\u5927\u5cf6\u3000\u8302
\n\u6b66\u3000\u5bdb\u3001\u5185\u85e4\u6ecb\u4eba\u3001\u4e2d\u6751\u7d18\u898f\u3001\u4e95\u4e0a\u6e80\u7a42\u3001\u65b0\u5cf6\u3000\u6842\u3001\u5143\u7530\u535a\u4e4b\u3001\u5927\u585a\u4f73\u6e80\u3001\u4f50\u3005\u6728\u5065\u4eba\u3001\u5357\u3000\u5065\u592a\u90ce\u3001\u83c5\u4e95\u7fa9\u5c1a\u3001\u718a\u8c37\u6d69\u53f8\u3001\u5927\u5cf6\u3000\u8302<\/p>\n
\u5b87\u90fd\u6728\u654f\u6d69\u3001\u9577\u8c37\u5ddd\u662d\u3001\u798f\u7530\u4e08\u4e86\u3001\u5b89\u9054\u4ec1\u3001\u5927\u5d8b\u6e05\u5b8f\u3001\u767d\u5009\u8ce2\u4e8c
\n\u7fa4\u99ac\u770c\u5185\u958b\u50ac\u306e\u30de\u30e9\u30bd\u30f3\u5927\u4f1a\u306e\u6551\u8b77\u306b\u95a2\u3059\u308b\u30a2\u30f3\u30b1\u30fc\u30c8\u8abf\u67fb<\/p>\n
\uff11\uff09Moderated poster
\n\u53cd\u753a\u79c0\u7f8e\u3001\u9ed2\u6ca2\u5e78\u55e3\u3001\u5c0f\u4fdd\u65b9\u512a\u3001\u5409\u7530\u304f\u306b\u5b50\u3001\u539f\u7530\u667a\u6210\u3001\u4e39\u4e0b\u6b63\u4e00\u3001\u5009\u6797\u6b63\u5f66\u3001\u6839\u5cb8\u4e00\u660e
\n\u5de6\u5ba4\u62e1\u5f35\u80fd\u306f\u5927\u52d5\u8108\u77f3\u7070\u5316\u306e\u72ec\u7acb\u3057\u305f\u898f\u5b9a\u56e0\u5b50\u3067\u3042\u308b<\/p>\n
\uff12\uff09Moderated poster
\n\u539f\u7530\u667a\u6210\u3001\u5c0f\u4fdd\u65b9\u512a\u3001\u9ed2\u6ca2\u5e78\u55e3\u3001\u53cd\u753a\u79c0\u7f8e\u3001\u5409\u7530\u304f\u306b\u5b50\u3001\u5c0f\u5ddd\u54f2\u4e5f\u3001\u5009\u6797\u6b63\u5f66\u3001\u6839\u5cb8\u4e00\u660e
\n\u7dad\u6301\u900f\u6790\u60a3\u8005\u306b\u304a\u3051\u308b\u5fc3\u62cd\u51fa\u91cf\u5897\u52a0\u306e\u6a5f\u5e8f\u3068\u5de6\u5ba4\u30a8\u30cd\u30eb\u30ae\u30fc\u30b3\u30b9\u30c8\u3068\u306e\u95a2\u9023<\/p>\n
\uff13\uff09Poster
\n\u539f\u7530\u667a\u6210\u3001\u9ed2\u6ca2\u5e78\u55e3\u3001\u6839\u5cb8\u4e00\u660e\u3001\u53cd\u753a\u79c0\u7f8e\u3001\u5009\u6797\u6b63\u5f66
\n\u5927\u52d5\u8108\u5f01\u72ed\u7a84\u75c7\u306e\u6700\u9ad8\u8840\u6d41\u901f\u5ea6\u53d6\u5f97\u65ad\u9762\u3068\u5f01\u5f62\u614b\u306b\u95a2\u3059\u308b\u691c\u8a0e<\/p>\n
\uff14\uff09Poster
\n\u5409\u7530\u304f\u306b\u5b50\u3001\u6839\u5cb8\u4e00\u660e\u3001\u9ed2\u6ca2\u5e78\u55e3\u3001\u5c0f\u4fdd\u65b9\u512a\u3001\u53cd\u753a\u79c0\u7f8e\u3001\u539f\u7530\u667a\u6210\u3001\u5009\u6797\u6b63\u5f66
\n\u80ba\u3046\u3063\u8840\u306b\u5bfe\u3059\u308bultrasound lung comets\u306b\u306f\u9ad8\u611f\u5ea6\u90e8\u4f4d\u304c\u5b58\u5728\u3059\u308b\u3002\u900f\u6790\u9593\u9694\u306e\u9055\u3044\u306b\u3088\u308b\u691c\u8a0e<\/p>\n
\uff15\uff09Poster
\n\u4e39\u7fbd\u52a0\u5948\u5b50\u3001\u9ed2\u6ca2\u5e78\u55e3\u3001\u53cd\u753a\u79c0\u7f8e\u3001\u68ee\u7530\u572d\u5b50\u3001\u751f\u99d2\u5353\u5b8f\u3001\u5ca1\u7530\u9855\u4e5f\u3001\u539f\u7530\u667a\u6210\u3001\u753a\u7530\u54f2\u7537\u3001\u6c60\u7530\u798e\u667a\u3001\u5c0f\u677f\u6a4b\u7d00\u901a\u3001\u5009\u6797\u6b63\u5f66\u3001\u6751\u4e0a\u6b63\u5df3
\n\u7d4c\u80f8\u58c1\u5fc3\u30a8\u30b3\u30fc\u56f3\u691c\u67fb\u3067\u7d4c\u904e\u89b3\u5bdf\u3057\u5f97\u305f\u50e7\u5e3d\u5f01\u975e\u7d30\u83cc\u6027\u8840\u6813\u6027\u5fc3\u5185\u819c\u708e\u306e\u4e00\u75c7\u4f8b<\/p>\n
\uff16\uff09\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0
\n\u5ca1\u7530\u9855\u4e5f\u3001\u9ed2\u6ca2\u5e78\u55e3\u3001\u6751\u4e0a\u6b63\u5df3
\n\u201c\u8cea\u304c\u9ad8\u304f\u3001\u4fe1\u983c\u3055\u308c\u308b\u5fc3\u30a8\u30b3\u30fc\u5ba4\u3092\u76ee\u6307\u3057\u3066\u201d
\n\u3000\u3000\u3000\u3000\u3000\uff5e\u30bd\u30ce\u30b0\u30e9\u30d5\u30a1\u30fc\u306e\u5ba2\u89b3\u7684\u8a55\u4fa1\u3068\u6559\u80b2\u52b9\u679c\u306e\u78ba\u8a8d\uff5e
\n\u201c\u5fc3\u30a8\u30b3\u30fc\u56f3\u691c\u67fb\u306b\u304a\u3051\u308b\u7cbe\u5ea6\u7ba1\u7406\u201d<\/p>\n
\u4f50\u85e4\u9ebb\u91cc\uff0c\u5927\u5cf6\u4e00\u771f\uff0c\u9234\u6728\u96c5\u6587\uff0c\u539f\u7530\u76f4\u4e4b\uff0c\u5009\u5cf6\u512a\u7406\u4e9c\uff0c\u4e0a\u91ce\u3000\u5b66\uff0c\u8302\u6728\u3000\u5145
\n\u95a2\u7bc0\u30ea\u30a6\u30de\u30c1\u6cbb\u7642\u4e2d\u306b\u767a\u75c7\u3057\u305f\u30cb\u30e5\u30fc\u30e2\u30b7\u30b9\u30c1\u30b9\u80ba\u708e(PCP)\u306e\u81e8\u5e8a\u7684\u691c\u8a0e\uff5e\u751f\u5b58\u4f8b\u3068\u6b7b\u4ea1\u4f8b\u306e\u6bd4\u8f03<\/p>\n
5\/23
\nNagasaka T,Takama N
\nEffects of Adaptive Servo Ventilation Therapy on Paroxysmal Atrial Fibrillation and Ventricualr tachycardia in Heart Failure Patients Due to Ischemic Heart Disease.<\/p>\n
5\/24
\n\uff11\uff09\t\u4f34\u91ce\u6f64\u4e00
\n\u6e2c\u5b9a\u65b9\u6cd5\u5909\u66f4\u306b\u3088\u308bGAD\u6297\u4f53\u5024\u306e\u5909\u5316\u3068\u7de9\u5f90\u9032\u884c\u578b1\u578b\u7cd6\u5c3f\u75c5\u306e\u81e8\u5e8a\u7d4c\u904e\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e<\/p>\n
2\uff09 \u4e2d\u91ce\u771f\u5f13\u3001\u798f\u7530\u4e09\u667a\u4ee3\u3001\u7530\u4e2d\u771f\u7d00\u5b50\u3001\u9577\u8c37\u5ddd\u65e9\u4ee3\u3001\u5973\u5c4b\u7531\u7f8e\u3001\u8a2d\u697d\u512a\u9999\u3001\u5b87\u90fd\u6728\u61b2\u5b50\u3001\u5b87\u90fd\u6728\u654f\u6d69
\n\u7cd6\u5c3f\u75c5\u624b\u5e33\u3092\u5229\u7528\u3057\u305f\u7cd6\u5c3f\u75c5\u814e\u75c7\u306e\u7642\u990a\u6307\u5c0e<\/p>\n
5\/25
\n\u5c71\u53e3\u662d\u4e09\u90ce\uff0c\u93d1\u6728\u5b5d\u4e4b\uff0c\u4e95\u4e0a\u771f\u4f50\u5b50\uff0c\u5927\u5cf6\u592e\u4e4b\uff0c\u5927\u4e45\u4fdd\u521d\u7f8e\uff0c\u5cf6\u7530\u68a8\u7d17\uff0c\u5c71\u7530\u8c4a\uff0c\u7530\u6751\u667a\u5b8f\uff0c\u5409\u5ddd\u5f25\u9808\u5b50\uff0c\u6a4b\u672c\u5e7e\u592a\uff0c\u96e8\u5bae\u9686\u592a
\n\u81bf\u80f8\u3084\u80ba\u708e\u968f\u4f34\u80f8\u6c34\u75c7\u4f8b\u306b\u5bfe\u3057\uff0c\u5c40\u6240\u9ebb\u9154\u4e0b\u80f8\u8154\u93e1\u65bd\u884c\u6642\u306b\u7d44\u7e54\u57f9\u990a\u3092\u884c\u3046\u610f\u7fa9<\/p>\n
\u5c0f\u677f\u6a4b\u7d00\u901a\u3001\u78ef\u3000\u9054\u4e5f\u3001\u5009\u6797\u6b63\u5f66
\n\u672a\u5206\u753b\u30d8\u30d1\u30ea\u30f3\u76ae\u4e0b\u6ce8\u7642\u6cd5\u3067\u809d\u6a5f\u80fd\u969c\u5bb3\u3092\u8a8d\u3081\u305f\u80ba\u585e\u6813\u75c7\u30cf\u30a4\u30ea\u30b9\u30af\u598a\u5a66\u306e2\u4f8b<\/p>\n
\u4f50\u91ce\u5e78\u6075\u3001\u4e2d\u91ce\u8003\u82f1\u3001\u9577\u5742\u5d07\u53f8\u3001\u4f50\u85e4\u4e07\u57fa\u4eba\u3001\u6885\u5c71\u3000\u6566\u3001\u8239\u7530\u7adc\u4e00\u3001\u5c0f\u677f\u6a4b\u7d00\u901a\u3001\u5009\u6797\u6b63\u5f66
\n\u814e\u52d5\u8108\u7834\u88c2\u3067\u767a\u75c7\u3057\u3001\u6b21\u4e16\u4ee3\u30b7\u30fc\u30af\u30a8\u30f3\u30b5\u30fc\u3092\u7528\u3044\u3066\u8a3a\u65ad\u306b\u81f3\u3063\u305f\u8840\u7ba1\u578b\u30a8\u30fc\u30e9\u30b9\u30c0\u30f3\u30ed\u30b9\u75c7\u5019\u7fa4\u306e\u4e00\u4f8b<\/p>\n
\u7530\u6751\u5cfb\u592a\u90de\u3001\u91d1\u53e4\u5584\u660e\u3001\u4e2d\u5cf6\u3000\u5fe0\u3001\u98ef\u585a\u8cb4\u58eb\u3001\u5009\u6797\u6b63\u5f66
\n\u901a\u5e38\u306eslow pathway ablation\u76f4\u5f8c\u306bsuperior slow pathway\u304c\u9855\u5728\u5316\u3057superior type fast-slow AVNRT\u304c\u8a98\u767a\u3055\u308c\u305f\u4e00\u4f8b.<\/p>\n
\u4f50\u85e4\u9ebb\u91cc
\n\u5f53\u9662\u306b\u304a\u3051\u308b\u9ad8\u6d41\u91cf\u9f3b\u30ab\u30cb\u30e5\u30e9\u306e\u4f7f\u7528\u72b6\u6cc1<\/p>\n
Yoshiaki Kaneko
\nElectophysiological characteristics and catheter ablation of atypical fast-slow atrioventricular nodal reentrant tachycardia.<\/p>\n
7\/13
\n\uff11)\tYoshiaki Kaneko
\nKeynote lecture: Unique Electrophysiological Characteristics of Superior Type Fast-slow Atrioventricular Nodal Reentrant Tachycardi. In: Symposium 14. Novel Insight into Paroxysmal Supraventricular Tachycardia. <\/p>\n
\uff12)\tShuntaro Tamura, Yoshiaki Kaneko, Tadashi Nakajima, Takashi Iizuka, Masahiko Kurabayashi
\nNovel Electrophysiological Evidence of Functionally Longitudinal Dissociation in the His Bundle: Paradoxical Penetration into AV Node During Ventricular Stimulation. <\/p>\n
\uff13)\tTakashi Iizuka, Yoshiaki Kaneko, Tadashi Nakajima, Tadanobu Irie, Shuntaro Tamura, Masahiko Kurabayashi
\nAtypical Fast-slow Atrioventricular Nodal Reentrant Tachycardia Apparently Mimicking Slow-fast Type due to Block at the Lower Common Pathway. <\/p>\n
\uff14)\tTadashi Nakajima, Yoshiaki Kaneko, Koji Kurosawa, Shuntaro Tamura, Takashi Iizuka, Tadanobu Irie, Masahiko Kurabayashi.
\nHypertrabeculation localized at left ventricular apex may be associated with life-threatening ventricular arrhythmias in Brugada Syndrome.<\/p>\n
\uff15)\tTaisuke Isikawa, Hiroyuki Mishima, Seiko Ohno, Takeshi Aiba, Yukiko Nakano, Yoshiyasu Aizawa, Tadashi Nakajima, Kenshi Hayashi, Nobuyuki Murakoshi, Nobue Yagihara, Hiroki Kimoto, Takeru Makiyama, Hiroshi Watanabe, Hiroshi Morita, Koh-Ichiro Yoshiura, Akihiko Nogami, Wataru Shimizu, Minoru Horie, Toshihiro Tanaka, Naomasa Makita.
\nRare Coding Variants in Genes Other Than SCN5A Are Minimal Genetic Burden on the Prognosis of Brugada Syndrome.<\/p>\n
\u4f34\u91ce\u6f64\u4e00
\n\u30ea\u30e9\u30b0\u30eb\u30c1\u30c9\u306b\u3088\u308b\u904b\u52d5\u4e2d\u306e\u5fc3\u62cd\u5fdc\u7b54\u5909\u5316\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e<\/p>\n
1\uff09\t\u85cd\u539f\u548c\u53f2
\nDCB\u6642\u4ee3\u306b\u304a\u3051\u308b\u30b9\u30c6\u30f3\u30c8\u518d\u72ed\u7a84\u306b\u5bfe\u3059\u308b\u6cbb\u7642\u6226\u7565\u3068\u3088\u3054\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e<\/p>\n
2\uff09\tAihara K,Kano H,Matsuno S,Suzuki S,Oikawa Y,Nagashima K,Kirigaya H,Aizawa T,Yajima J,Yamashita T
\nStrategies and Long-Term Outcomes in the Treatment of Stent Restenosis in the era of Drug-Coated Balloon<\/p>\n
3\uff09\t\u4f50\u9ce5\u572d\u4ecb
\n\u65b0\u898f\u51a0\u52d5\u8108\u72ed\u7a84\u306b\u5bfe\u3059\u308bDCB\u5358\u72ec\u6cbb\u7642\u3068\u7b2c2-3\u4e16\u4ee3DES\u306e\u6210\u7e3e\u6bd4\u8f03<\/p>\n
4\uff09\t\u7530\u53e3\u54f2\u4e5f
\n\u8108\u9aa8\u52d5\u8108\u306e\u8840\u6813\u6027\u75c5\u5909\u306b\u5bfe\u3059\u308bOPTIMO\u306b\u3088\u308b\u65b0\u3057\u3044\u672b\u68a2\u4fdd\u8b77\u6cd5\u306e\u6709\u7528\u6027<\/p>\n
5\uff09\t\u672c\u591a\u6d0b\u4ecb
\n\u4f4e\u5fc3\u6a5f\u80fd\u3092\u5448\u3059\u308b\u60a3\u8005\u306b\u304a\u3051\u308b\u6162\u6027\u5b8c\u5168\u9589\u585e\u6027\u3078\u306e\u30ab\u30c6\u30fc\u30c6\u30eb\u6cbb\u7642\u306e\u6210\u7e3e\u3068\u5fc3\u6a5f\u80fd\u3078\u306e\u5f71\u97ff<\/p>\n
6\uff09\t\u672c\u591a\u6d0b\u4ecb
\nTAVI\u5f8c\u6804\u990a\u72b6\u614b\u306e\u60aa\u5316\u306f\u4e88\u5f8c\u4e0d\u826f\u56e0\u5b50\u3067\u3042\u308b<\/p>\n
7\uff09\t\u672c\u591a\u6d0b\u4ecb
\n\u5fc3\u623f\u7d30\u52d5\u3068\u5927\u817f\u819d\u7aa9\u52d5\u8108\u9818\u57df\u3078\u306e\u30b9\u30c6\u30f3\u30c8\u7559\u7f6e\u5f8c\u306e\u9589\u585e\u3068\u95a2\u4fc2<\/p>\n
8\uff09\t\u672c\u591a\u6d0b\u4ecb
\nTAVI\u306b\u304a\u3051\u308b\u7a7f\u523a\u90e8\u5408\u4f75\u75c7\u3068\u30e9\u30fc\u30cb\u30f3\u30b0\u30ab\u30fc\u30d6<\/p>\n
9\uff09\t\u677e\u5c3e\u5f25\u679d
\ndual LAD\u306e\u6025\u6027\u51a0\u75c7\u5019\u7fa4\u3067\u30b9\u30c6\u30f3\u30c8\u30b9\u30c6\u30e9\u30c6\u30b8\u30fc\u3068\u8840\u6813\u306b\u96e3\u6e0b\u3057\u305f\u4e00\u4f8b<\/p>\n
10\uff09\t\u677e\u5c3e\u5f25\u679d
\n\u8133\u6897\u585e\u306e\u5371\u967a\u56e0\u5b50\u3068\u3057\u3066\u306e\u672b\u68a2\u52d5\u8108\u75be\u60a3\u2015\u672b\u68a2\u52d5\u8108\u75be\u60a3\u60a3\u8005\u306b\u304a\u3051\u308b\u8133\u6897\u585e\u304a\u3088\u3073\u9838\u52d5\u8108\u72ed\u7a84\u306e\u6709\u75c5\u7387<\/p>\n
11\uff09\t\u6751\u7530\u667a\u884c
\n\u7d4c\u76ae\u7684\u51a0\u52d5\u8108\u30a4\u30f3\u30bf\u30fc\u30d9\u30f3\u30b7\u30e7\u30f3\u3092\u65bd\u884c\u3057\u305f\u5fc3\u623f\u7d30\u52d5\u3092\u5408\u4f75\u3059\u308b\u60a3\u8005\u306b\u304a\u3051\u308b\u77ed\u671f\u4e09\u8ca1\u4f75\u7528\u6297\u8840\u6813\u7642\u6cd5<\/p>\n
12\uff09\t\u4e2d\u91ce\u8003\u82f1
\n\u5074\u679d\u9589\u585e\u30ea\u30b9\u30af\u306e\u9ad8\u3044\u75c5\u5909\u306b\u5bfe\u3059\u308bJailed Corsair Technique\u306e\u6210\u7e3e<\/p>\n
13\uff09\t\u83c5\u91ce\u5e78\u592a
\n\u73fe\u5728\u306e\u85ac\u5264\u6eb6\u51fa\u6027\u30b9\u30c6\u30f3\u30c8\u3092\u7528\u3044\u305f\u5de6\u4e3b\u7ba1\u90e8\u306b\u5bfe\u3059\u308bSimple Crossover Stenting\u306e\u5b89\u5168\u6027\u3068\u6709\u52b9\u6027<\/p>\n
\uff11)\tUmeyama A.
\nGood adherence is important factor for adaptive servo-ventilation treatment for eiderly patients with heart failure<\/p>\n
\uff12)\tTomono J.
\nImpaired heart rate response to exercise in the mild degree of dysglycemia<\/p>\n
1\uff09\t\u5009\u6797\u6b63\u5f66
\n\u30e9\u30f3\u30c1\u30e7\u30f3\u30bb\u30df\u30ca\u30fc\uff1a\u30a8\u30d3\u30c7\u30f3\u30b9\u306b\u5b66\u3076\u7cd6\u5c3f\u75c5\u306e\u5fc3\u8840\u7ba1\u5408\u4f75\u75c7\u306e\u30e1\u30ab\u30cb\u30ba\u30e0\u3068\u6cbb\u7642\u6226\u7565<\/p>\n
2\uff09\t\u5c0f\u677f\u6a4b\u7d00\u901a\u3001\u30a6\u30f3\u30d0\u30e9\u30ef\u30f3 \u30e8\u30ae\u3001\u53e4\u5ddd\u3000\u5e0c\u3001\u78ef\u3000\u9054\u4e5f\u3001\u5009\u6797\u6b63\u5f66
\n\u5fc3\u7b4b\u30a8\u30cd\u30eb\u30ae\u30fc\u4ee3\u8b1d\u3068\u30b9\u30c8\u30ec\u30b9\u53cd\u5fdc<\/p>\n
3\uff09\t\u9577\u5742\u5d07\u53f8\u3001\u8239\u7530\u7adc\u4e00\u3001\u7b20\u9593\u3000\u5468\u3001\u9ad8\u9593\u5178\u660e\u3001\u5c0f\u677f\u6a4b\u7d00\u901a\u3001\u5009\u6797\u6b63\u5f66
\n\u4f53\u5916\u5f0f\u819c\u578b\u4eba\u5de5\u80ba\u3092\u8981\u3059\u308b\u5fc3\u539f\u6027\u30b7\u30e7\u30c3\u30af\u304a\u3088\u3073\u5fc3\u505c\u6b62\u60a3\u8005\u306b\u304a\u3051\u308b\u4e88\u5f8c\u4e88\u6e2c\u56e0\u5b50\u306e\u691c\u8a0e<\/p>\n
4\uff09\t\u6885\u5c71\u3000\u6566\u3001\u9ad8\u9593\u5178\u660e\u3001\u5009\u6797\u6b63\u5f66
\n\u9ad8\u9f62\u5fc3\u4e0d\u5168\u60a3\u8005\u306b\u5bfe\u3059\u308bASV\u6cbb\u7642\u306e\u30a2\u30c9\u30d2\u30a2\u30e9\u30f3\u30b9\u306e\u91cd\u8981\u6027\u306e\u691c\u8a0e<\/p>\n
5\uff09\t\u9ad8\u9593\u5178\u660e
\n\u6cbb\u7642\u306b\u82e6\u616e\u3057\u305f\u91cd\u75c7\u80ba\u52d5\u8108\u6027\u80ba\u9ad8\u8840\u5727\u75c7\u306e\u4e00\u4f8b\u2015\u65e9\u671f\u767a\u898b\u306e\u91cd\u8981\u6027\u2015<\/p>\n
\u963f\u4e45\u6fa4\u66a2\u6d0b
\n\u826f\u597d\u306a\u7d4c\u904e\u3092\u8fbf\u3063\u305f\u8178\u7ba1\u6c17\u816b\u75c7\u306e2\u75c7\u4f8b<\/p>\n
Nagasaka T.
\nLong-term Outcome of Drug Coated Balloons in Patients with Stent Edge Restenosis<\/p>\n
9\/22
\n\u78ef\u9054\u4e5f,Suman Shrestha,\u9808\u6c38\u6d69\u7ae0\u3001\u5009\u6797\u6b63\u5f66
\nSerum FABP4 is removed by the kidney via glomerular filtration and megalin-mediated reabsorprion<\/p>\n
10\/11<\/p>\n
\uff11)\t\u6839\u5cb8\u4e00\u660e
\nHow to manage cardiovascular complications during cancer therapy<\/p>\n
10\/12<\/p>\n
\uff12)\t\u5c0f\u677f\u6a4b\u7d00\u901a
\n\u7dda\u7dad\u82bd\u7d30\u80de\u5897\u6b96\u56e0\u5b5021\u306f\u6025\u6027\u5fc3\u7b4b\u6897\u585e\u306b\u3088\u308b\u4ee3\u8b1d\u30b9\u30c8\u30ec\u30b9\u3092\u793a\u3059\u65b0\u305f\u306a\u30d0\u30a4\u30aa\u30de\u30fc\u30ab\u30fc\u3067\u3042\u308b<\/p>\n
10\/13<\/p>\n
\uff13)\t\u5b89\u9054\u3000\u4ec1
\n\u6559\u80b2\u8b1b\u6f14
\n\u5fc3\u4e0d\u5168\u8a3a\u7642\u306b\u304a\u3051\u308b\u5fc3\u81d3\u30ea\u30cf\u30d3\u30ea\u30c6\u30fc\u30b7\u30e7\u30f3\u306e\u91cd\u8981\u6027<\/p>\n
10\/17<\/p>\n
\uff11)\tKaneko Y.
\nHow to Ablate Atypical AVNRT Utilizing Variant of Slow Pathways? In: PSVT 02: How I Overcome the Challenging Case of AVNRT.<\/p>\n
10\/19<\/p>\n
\uff12)\tKaneko Y.,Nakajima T.,Iizuka T.,Tamura S.,Kurabayashi M.
\nApplication of V-A-A-V Response Immediately after Ventricular Induction\/Entrainment to Discriminate Atypical Atrioventricular Nodal Reentrant Tachycardia from Atrial Tachycardia. Oct 19, 2018, 11th Asia Pacific Heart Rhythm Society Scientific Session(APHRS 2018) , Taipei.<\/p>\n
10\/20<\/p>\n
\uff13)\tNakajima T.
\nEpinephrine-Induced Marked QT Prolongation in Patients with Type-3 Long QT Syndrome<\/p>\n
\uff11)\t\u5c0f\u66ae\u771f\u4e5f\u3001\u4e39\u4e0b\u6b63\u4e00\u3001\u5ead\u524d\u91ce\u83ca\u3001\u4f50\u9ce5\u572d\u4ecb\u3001\u4eca\u4e95\u7f8e\u667a\u5b50\u3001\u4f50\u3005\u6728\u5b5d\u5fd7\u3001\u5185\u7530\u6d69\u592a\u90ce\u3001\u661f\u91ce\u572d\u6cbb\u3001\u5de5\u85e4\u5ee3\u5927\u3001\u5742\u4e95\u4fca\u82f1
\n\u819d\u4e0b\u75c5\u5909\u306e\u6cbb\u7642\u3067IVUS\u304c\u65ad\u88c2\u3057\u8840\u7ba1\u5185\u306b\u53d6\u308a\u6b8b\u3055\u308c\u305f\u304cDistal puncture\u3092\u7528\u3044\u3066\u53d6\u308a\u51fa\u3059\u3053\u3068\u306b\u6210\u529f\u3057\u305f\u4e00\u4f8b<\/p>\n
\uff12)\t\u571f\u4e95\u3000\u5b8f\u3001\u585a\u7530\u4fca\u4e00
\nFiltrap\u3092\u56de\u53ce\u30ab\u30c6\u3092\u7528\u3044\u305a\u629c\u53bb\u3059\u308b\u3053\u3068\u306b\u3088\u308aGC\u5185\u306b\u8131\u843d\u3057\u305f\u5de8\u5927\u8840\u6813\u3092\u56de\u53ce\u3057\u5f97\u305f\u4e0b\u58c1AMI\u306e\u4e00\u4f8b<\/p>\n
\uff13)\t\u85cd\u539f\u548c\u53f2\u3001\u8239\u7530\u7adc\u4e00\u3001\u6751\u4e0a\u6587\u5d07\u3001\u77f3\u6a4b\u6d0b\u5e73\u3001\u53cd\u753a\u79c0\u7f8e\u3001\u9577\u5742\u5d07\u53f8\u3001\u9ad8\u9593\u5178\u660e\u3001\u8239\u7530\u7adc\u4e00
\n\u5de6\u4e3b\u7ba1\u90e8\u306e\u5206\u5c90\u90e8\u75c5\u5909\u306b\u5bfe\u3057\u3066DCA\u3092\u7528\u3044\u3066V\u30b9\u30c6\u30f3\u30c8\u3092\u884c\u3044\u3001\uff13D-OCT\u3067\u89b3\u5bdf\u3057\u305f\u4e00\u4f8b<\/p>\n
\uff14)\t\u5c0f\u66ae\u771f\u4e5f\u3001\u4e39\u4e0b\u6b63\u4e00\u3001\u5ead\u524d\u91ce\u83ca\u3001\u4f50\u9ce5\u572d\u4ecb\u3001\u4eca\u4e95\u7f8e\u667a\u5b50\u3001\u4f50\u3005\u6728\u5b5d\u5fd7\u3001\u5185\u7530\u6d69\u592a\u90ce\u3001\u661f\u91ce\u572d\u6cbb\u3001\u5de5\u85e4\u5ee3\u5927\u3001\u5742\u4e95\u4fca\u82f1
\nSubintimal contrast angiography\uff5eSUICA\uff5e\u3092\u4f7f\u7528\u3057\u305f\u75c7\u4f8b<\/p>\n
10\/27
\n\u9808\u6c38\u6d69\u7ae0
\n\u6025\u6027\u5fc3\u81d3\u30a4\u30d9\u30f3\u30c8\u306e\u8a3a\u65ad\u3001\u91cd\u75c7\u5ea6\u30de\u30fc\u30ab\u30fc\u3068\u3057\u3066\u306e\u7dda\u7dad\u82bd\u7d30\u80de\u5897\u6b96\u56e0\u5b50FGF21\u306e\u75c5\u614b\u610f\u7fa9<\/p>\n
\uff11)\t\u5c0f\u677f\u6a4b\u7d00\u901a
\n\u5316\u5b66\u7642\u6cd5\u4e2d\u306b\u6cbb\u7642\u95a2\u9023\u8840\u6813\u75c7\u3068\u601d\u308f\u308c\u308b\u4e0b\u80a2\u6025\u6027\u52d5\u8108\u9589\u585e\u75c7\u3092\u767a\u75c7\u3057\u305f\u7cbe\u5de3\u816b\u760d\u306e\u4e00\u4f8b<\/p>\n
\uff12)\t\u5c0f\u677f\u6a4b\u7d00\u901a
\n\u62c5\u764c\u60a3\u8005\u306b\u5408\u4f75\u3057\u305f\u9759\u8108\u8840\u6813\u585e\u6813\u75c7\u306b\u5bfe\u3059\u308b\u76f4\u63a5\u7d4c\u53e3\u6297\u51dd\u56fa\u85ac\u306e\u6709\u52b9\u6027\u306e\u691c\u8a0e<\/p>\n
\uff13)\t\u4e2d\u91ce\u8003\u82f1
\n\u76f4\u63a5\u7d4c\u53e3\u6297\u51dd\u56fa\u85ac\u306e\u5185\u670d\u4e0b\u3067\u767a\u75c7\u3057\u305f\u975e\u7d30\u83cc\u6027\u8840\u6813\u6027\u5fc3\u5185\u819c\u708e\u306e2\u4f8b<\/p>\n
\u524d\u91ce\u654f\u5b5d\u3001\u5c71\u53e3\u88d5\u81e3\u3001\u9577\u8c37\u5ddd\u3000\u4fe1
\n\u80ba\u304c\u3093\u60a3\u8005\u306e\u30ea\u30cf\u30d3\u30ea\u30c6\u30fc\u30b7\u30e7\u30f3\u306e\u5f53\u79d1\u306b\u304a\u3051\u308b\u73fe\u72b6\u3068\u8ab2\u984c<\/p>\n
11\/10\u516c\u958b\u7814\u7a76\u4f1a<\/p>\n
1\uff09\t\u98ef\u585a\u8cb4\u58eb\u3001\u91d1\u53e4\u5584\u660e\u3001\u4e2d\u5cf6\u5fe0\u3001\u7530\u6751\u5cfb\u592a\u90de\u3001\u5009\u6797\u6b63\u5f66 \uff0e
\nsuperior slow pathway\u3092\u4ecb\u3059\u308bslow-slow \u623f\u5ba4\u7d50\u7bc0\u30ea\u30a8\u30f3\u30c8\u30ea\u30fc\u6027\u983b\u62cd\u306e\u4e00\u4f8b<\/p>\n
2\uff09\t\u7530\u6751\u5cfb\u592a\u90de\u3001\u91d1\u53e4\u5584\u660e\u3001\u4e2d\u5cf6\u5fe0\u3001\u98ef\u585a\u8cb4\u58eb\u3001\u5009\u6797\u6b63\u5f66\uff0e
\n\u901a\u5e38\u306eslow pathway ablation\u76f4\u5f8c\u306bsuperior slow pathway\u304c\u9855\u5728\u5316\u3057superior type fast-slow AVNRT\u304c\u8a98\u767a\u3055\u308c\u305f\u4e00\u4f8b\uff0e<\/p>\n
3\uff09\t\u7530\u6751\u5cfb\u592a\u90de\u3001\u91d1\u53e4\u5584\u660e\u3001\u4e2d\u5cf6\u5fe0\u3001\u98ef\u585a\u8cb4\u58eb\u3001\u5009\u6797\u6b63\u5f66\uff0e
\n\u5fc3\u5ba4\u30a8\u30f3\u30c8\u30ec\u30a4\u30f3\u30e1\u30f3\u30c8\u523a\u6fc0\u306e\u53cd\u5fdc\u304c\u7570\u306a\u308b\uff12\u3064\u306e\u983b\u62cd\u3092\u6709\u3057\u305f\u4e00\u4f8b\uff0e<\/p>\n
4\uff09\t\u9577\u8c37\u5ddd\u3000\u5bdb\u3001\u91d1\u53e4\u5584\u660e\u3001\u4e2d\u5cf6\u5fe0\u3001\u98ef\u585a\u8cb4\u58eb\u3001\u7530\u6751\u5cfb\u592a\u90de\u3001\u5009\u6797\u6b63\u5f66\uff0e
\n\u5b8c\u5168\u623f\u5ba4\u30d6\u30ed\u30c3\u30af\u306bslow pathway \u3092\u4ecb\u3059\u308b\u30da\u30fc\u30b9\u30e1\u30fc\u30ab\u8d77\u56e0\u983b\u62cd\u3092\u4f75\u767a\u3057\u305f\u4e00\u4f8b\uff0e
\n11\/11\u7814\u7a76\u30bb\u30df\u30ca\u30fc<\/p>\n
5\uff09 \u91d1\u53e4\u5584\u660e
\n\u7279\u6b8a\u306a\u623f\u5ba4\u7d50\u7bc0\u30ea\u30a8\u30f3\u30c8\u30ea\u30fc\u6027\u983b\u62cd\u306e\u30a2\u30d6\u30ec\u30fc\u30b7\u30e7\u30f3\uff0e<\/p>\n
11\/11<\/p>\n
\uff11)\tNakano T.,Takama N.,Kurabayashi M.
\nReassessment After Six Months of Treatment With Adaptibe Servo Ventilation Can Predict Future Fatal Cardiovascular Events in Patients With Heart Failure With Reduced Ejection Fraction<\/p>\n
\uff12)\tSunaga H.,Koitabashi N.,Matsui H.,Iso T.,Yokoyama T.,Kurabayashi M.
\nElevation of Serum Fibroblast Growth Factor 21 in Patients With Acute Myocardial Infarction:A Potential Role of Ampk Activation Following Sympathetic Overdrive.<\/p>\n
11\/12<\/p>\n
\uff13)\tIwase H.,Koitabashi N.,Kasama S.,Nagasaka T.,Funada R.,Takama N.,Kurabayashi M.
\nRivaroxaban Administration Early Regression of Thrombus Burden in Venous Thromboembolism<\/p>\n
\uff14)\tFurukawa N.,Koitabashi N.,Matsui H.,Yogi Umbarawan,Yokoyama T.,Kurabayashi M.
\nSacubitril\/Valsartan Improves Passive Myocardial Stiffness Associated with Titin Phosphorylation in Diabetic Mice Heart.<\/p>\n
\uff15)\tMatsui H, Sunaga H, Umbarawan Y, Iso, Koitabashi N, Matsuzaka T, Shimano H, Yokoyama T, Kurabayashi M.\u3000Genetic deletion of Elovl6 in cardiac myocytes suppresses pressure overload-induced cardiac hypertrophy and remodeling through activation of AMPK-KLF4 signaling<\/p>\n
11\/30
\nYamaguchi K,Yamaguchi A,Takemura M,Hara K,Maeno T,Hisada T
\nClinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with interstitial pneumonia<\/p>\n
\u5c0f\u677f\u6a4b\u7d00\u901a
\n\u76f4\u63a5\u7d4c\u53e3\u6297\u51dd\u56fa\u85ac\u3067\u9759\u8108\u585e\u6813\u306f\u6539\u5584\u3057\u305f\u304c\u52d5\u8108\u585e\u6813\u3092\u767a\u75c7\u3057\u305f2\u4f8b<\/p>\n
\uff11)\t\u5927\u77f3\u7531\u7f8e\u5b50
\n\u7559\u5b66\u306e\u30b9\u30b9\u30e1\u2015\u4e16\u754c\u3068\u3064\u306a\u304c\u308a\u30ad\u30e3\u30ea\u30a2\u3092\u62d3\u3053\u3046\u2015<\/p>\n
\uff12)\t\u4e2d\u5cf6\u77e5\u8cb4
\n\u597d\u9178\u7403\u6027\u591a\u767a\u8840\u7ba1\u708e\u6027\u8089\u82bd\u816b\u75c7\u306b\u4e21\u5fc3\u5ba4\u5185\u8840\u6813\u3092\u5408\u4f75\u3057\u305f\u30ec\u30d5\u30ec\u30eb\u5fc3\u5185\u819c\u708e\u306e\u4e00\u4f8b<\/p>\n
\uff13)\t\u963f\u4e45\u6fa4\u66a2\u6d0b
\n\u7279\u767a\u6027\u4e0a\u8178\u9593\u819c\u52d5\u8108\u89e3\u96e2\u306b\u52d5\u8108\u7624\u5f62\u6210\u3092\u5408\u4f75\u3057\u3001\u75c5\u7406\u5b66\u7684\u306b\u5206\u7bc0\u72b6\u4e2d\u819c\u878d\u89e3\uff08SAM\uff09\u306e\u95a2\u4e0e\u304c\u8a3c\u660e\u3055\u308c\u305f\u4e00\u4f8b<\/p>\n
\u7b2c35\u56de\u56fd\u969b\u5fc3\u81d3\u7814\u7a76\u5b66\u4f1a\u65e5\u672c\u90e8\u4f1a\uff08ISHR\uff09<\/p>\n
12\/7<\/p>\n
1\uff09Nozomi Furukawa
\nSacubitril\/Valsartan Improves Passive Myocardial Stiffness via increased Titin Phosphorylation in Diabetic Mice<\/p>\n
2\uff09Suman Shrestha O2-IS-4 Circulating FABP4 is eliminated by the kidney via glomerular filtration followed by megalin-mediated reabsorption<\/p>\n
12\/8
\n\u9808\u6c38\u6d69\u7ae0
\nFGF21\u306f\u6025\u6027\u5fc3\u7b4b\u6897\u585e\u306b\u304a\u3051\u308b\u5fc3\u7b4b\u4ee3\u8b1d\u30b9\u30c8\u30ec\u30b9\u3092\u793a\u3059\u65b0\u305f\u306a\u30d0\u30a4\u30aa\u30de\u30fc\u30ab\u30fc\u3067\u3042\u308b<\/p>\n","protected":false},"excerpt":{"rendered":"
BCVR\u30002018.1.6-7\uff08\u6771\u4eac\uff09 1\/6 \uff11\uff09 YOGI UMBARAWAN Vital role of glucose as biomass synthesis substrate in CD36 deficie […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":313,"menu_order":55,"comment_status":"closed","ping_status":"closed","template":"tpl_results.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-317","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/pages\/317","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=317"}],"version-history":[{"count":1,"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/pages\/317\/revisions"}],"predecessor-version":[{"id":318,"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/pages\/317\/revisions\/318"}],"up":[{"embeddable":true,"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/pages\/313"}],"wp:attachment":[{"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=317"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}